Log in

NASDAQ:CDLXCardlytics Stock Price, Forecast & News

$68.09
+5.51 (+8.80 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$61.27
Now: $68.09
$68.40
50-Day Range
$39.84
MA: $50.74
$70.74
52-Week Range
$22.22
Now: $68.09
$107.50
Volume811,166 shs
Average Volume939,544 shs
Market Capitalization$1.84 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.37
Cardlytics, Inc. operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. It also provides solutions that enable marketers and marketing service providers to leverage the power of purchase intelligence outside the banking channel. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Read More
Cardlytics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.1Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.79 out of 5 stars


Industry, Sector and Symbol

Industry Computer programming, data processing, & other computer related
Sub-IndustryN/A
Current SymbolNASDAQ:CDLX
CUSIPN/A
Phone888-798-5802

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$210.43 million
Book Value$5.13 per share

Profitability

Net Income$-17,140,000.00

Miscellaneous

EmployeesN/A
Market Cap$1.84 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive CDLX News and Ratings via Email

Sign-up to receive the latest news and ratings for CDLX and its competitors with MarketBeat's FREE daily newsletter.

Cardlytics (NASDAQ:CDLX) Frequently Asked Questions

How has Cardlytics' stock been impacted by COVID-19 (Coronavirus)?

Cardlytics' stock was trading at $45.83 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CDLX stock has increased by 48.6% and is now trading at $68.09. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cardlytics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cardlytics.

When is Cardlytics' next earnings date?

Cardlytics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Cardlytics.

How were Cardlytics' earnings last quarter?

Cardlytics Inc (NASDAQ:CDLX) released its quarterly earnings results on Monday, May, 11th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.09. The firm had revenue of $45.51 million for the quarter, compared to analysts' expectations of $42.97 million. Cardlytics had a negative return on equity of 19.42% and a negative net margin of 11.08%. Cardlytics's quarterly revenue was up 26.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.23) earnings per share. View Cardlytics' earnings history.

What guidance has Cardlytics issued on next quarter's earnings?

Cardlytics issued an update on its first quarter 2020 After-Hours earnings guidance on Tuesday, March, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $43.5-46.5 million, compared to the consensus revenue estimate of $52.77 million.

What price target have analysts set for CDLX?

7 brokerages have issued 12 month price objectives for Cardlytics' stock. Their forecasts range from $26.00 to $55.00. On average, they anticipate Cardlytics' stock price to reach $48.50 in the next twelve months. This suggests that the stock has a possible downside of 28.8%. View analysts' price targets for Cardlytics.

Has Cardlytics been receiving favorable news coverage?

Press coverage about CDLX stock has been trending positive recently, according to InfoTrie. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cardlytics earned a daily sentiment score of 2.8 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news aboutCardlytics.

Who are some of Cardlytics' key competitors?

What other stocks do shareholders of Cardlytics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include Alibaba Group (BABA), Trade Desk (TTD), Advanced Micro Devices (AMD), NVIDIA (NVDA), Caterpillar (CAT), Roku (ROKU), Micron Technology (MU), Netflix (NFLX), Square (SQ) and Walt Disney (DIS).

Who are Cardlytics' key executives?

Cardlytics' management team includes the following people:
  • Mr. Scott D. Grimes, Co-Founder, CEO & Director (Age 56)
  • Ms. Lynne Marie Laube, Co-Founder, COO & Director (Age 49)
  • Mr. David Evans, CFO & Head of Corp. Devel.
  • Mr. Sathish Gaddipati, Chief Technology Officer (Age 52)
  • Mr. Kirk L. Somers, Chief Legal & People Officer (Age 54)

When did Cardlytics IPO?

(CDLX) raised $76 million in an initial public offering on Friday, February 9th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan served as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

What is Cardlytics' stock symbol?

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

Who are Cardlytics' major shareholders?

Cardlytics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include CAS Investment Partners LLC (14.65%), Wellington Management Group LLP (4.69%), BlackRock Inc. (4.43%), Grantham Mayo Van Otterloo & Co. LLC (3.00%), JS Capital Management LLC (2.02%) and Frontier Capital Management Co. LLC (2.05%). Company insiders that own Cardlytics stock include Aimia Inc, Andrew Christiansen, Bryce Youngren, Clifford Sosin, David Leslie Adams, David Thomas Evans, John V Balen, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Polaris Venture Management Co, Scott D Grimes and Tony Weisman. View institutional ownership trends for Cardlytics.

Which institutional investors are selling Cardlytics stock?

CDLX stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Deutsche Bank AG, Driehaus Capital Management LLC, BNP Paribas Arbitrage SA, Invesco Ltd., Morgan Stanley, Morgan Stanley, and Nuveen Asset Management LLC. Company insiders that have sold Cardlytics company stock in the last year include Aimia Inc, Andrew Christiansen, Bryce Youngren, David Leslie Adams, David Thomas Evans, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Polaris Venture Management Co, Scott D Grimes, and Tony Weisman. View insider buying and selling activity for Cardlytics.

Which institutional investors are buying Cardlytics stock?

CDLX stock was acquired by a variety of institutional investors in the last quarter, including CAS Investment Partners LLC, JPMorgan Chase & Co., Grantham Mayo Van Otterloo & Co. LLC, THB Asset Management, Rockefeller Capital Management L.P., Harspring Capital Management LLC, Frontier Capital Management Co. LLC, and Lord Abbett & CO. LLC. Company insiders that have bought Cardlytics stock in the last two years include Clifford Sosin, and John V Balen. View insider buying and selling activity for Cardlytics.

How do I buy shares of Cardlytics?

Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cardlytics' stock price today?

One share of CDLX stock can currently be purchased for approximately $68.09.

How big of a company is Cardlytics?

Cardlytics has a market capitalization of $1.84 billion and generates $210.43 million in revenue each year. The company earns $-17,140,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

What is Cardlytics' official website?

The official website for Cardlytics is www.cardlytics.com.

How can I contact Cardlytics?

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at 888-798-5802 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.